SB202190 is a selective and specific p38 MAPK inhibitor. It affects the p38 MAPK signaling pathway, and by blocking p38 phosphorylation and activation, it effectively inhibits apoptosis, inflammation, and tumor metastasis, while promoting stem cell survival.
SB202190 Mechanism of Action: p38 MAPK Inhibition in Tumor Cell Research
SB202190 MOA：Targeting p38 MAPK/ERK Pathway for Oncology and Cancer Research